Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 9/20 | 0.48 |
| ▸ | THRB | P10828 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22640005 | 0.82 | GAA (1.00) | GAAALDH1A1TP53THRBMAPT | |
| SCHEMBL24202463 | 0.77 | ALDH1A1 (0.50) | GAAALDH1A1TP53THRBMAPT | |
| SCHEMBL4573845 | 0.74 | ALDH1A1 (0.48) | GAAALDH1A1TP53THRB | |
| SCHEMBL873381 | 0.73 | PTGDR2 (0.53) | GAAALDH1A1MAPTLMNA | |
| SCHEMBL263398 | 0.72 | ALDH1A1 (0.45) | GAAALDH1A1TP53THRB | |
| SCHEMBL1243700 | 0.72 | TP53 (0.72) | GAAALDH1A1TP53THRBMAPT | |
| SCHEMBL1267025 | 0.70 | ALDH1A1 (0.45) | GAAALDH1A1TP53THRBLMNA | |
| SCHEMBL10282380 | 0.70 | ALDH1A1 (0.42) | GAAALDH1A1TP53THRB | |
| SCHEMBL13995833 | 0.69 | GAA (0.43) | GAAALDH1A1TP53THRBMAPT | |
| SCHEMBL18256087 | 0.69 | ALDH1A1 (0.43) | GAAALDH1A1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156651-A1 | Heterocyclylethylbenzamide Derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-1871744-B1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2009-01-07 | — | — | EP | disclosed |
| EP-1871744-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108792-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2006-10-19 | — | — | WO | disclosed |
| EP-1710237-A1 | New heterocyclylethylbenzamide derivatives | Bayer CropScience S.A. (FR) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156651-A1 | Heterocyclylethylbenzamide Derivatives | CYP1A2, CYP51A1, CYP1B1 | GAA 38/4885ALDH1A1 787/4885TP53 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.